Rising Biosciences (Rising Biosciences) Debt-to-Asset : 0.00 (As of . 20)

View and export this data going back to . Start your Free Trial

What is Rising Biosciences Debt-to-Asset?

Rising Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. Rising Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. Rising Biosciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in . 20 was $0.00 Mil.

Rising Biosciences Debt-to-Asset Historical Data

The historical data trend for Rising Biosciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences Debt-to-Asset Chart

Rising Biosciences Annual Data

Trend

Debt-to-Asset

Rising Biosciences Quarterly Data

Debt-to-Asset

Competitive Comparison of Rising Biosciences's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Rising Biosciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rising Biosciences's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rising Biosciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Rising Biosciences's Debt-to-Asset falls into.

Rising Biosciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Rising Biosciences's Debt-to-Asset for the fiscal year that ended in . 20 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(	+	)	/
	=	N/A

Rising Biosciences's Debt-to-Asset for the quarter that ended in . 20 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(	+	)	/
	=	N/A

Rising Biosciences (GREY:RBII) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Rising Biosciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Rising Biosciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Rising Biosciences (Rising Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Debt-to-Asset

Traded in Other Exchanges

N/A

Address

1180 Cleveland Road, Sandusky, OH, USA, 44870

Website

http://www.risingbiosciences.com

Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.